Radioactive Iodine Resistant Papillary Thyroid Cancer “Redifferentiated” With Dabrafenib

Background: Differentiated thyroid cancers (DTC) make up 95% of all thyroid cancers. Radioactive iodine therapy (RAI Rx) is an integral part of DTC management. However, 5-15% of DTC and 50% of metastatic DTC become resistant to RAI Rx and carries a 10-year survival of only 10%. One of the newer ther...

Full description

Saved in:
Bibliographic Details
Published in:J Endocr Soc
Main Authors: Zayouna, Christine, Sonnabend, Hajerah, Amblee, Ambika
Format: Artigo
Language:Inglês
Published: Oxford University Press 2021
Subjects:
Thyroid
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090069/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1833
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items